Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the role of ruxolitinib (Jakafi) in patients with polycythemia vera (PV), a myeloproliferative neoplasm of the bone marrow.
The standard of care for patients with PV who are at high risk of thrombosis is hydroxyurea (Hydrea), a mild chemotherapy. However, Verstovsek says this does not work with all patients; about 20% of patients will develop an intolerance or resistance to the treatment.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More